3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
15
Carcinoma, Hepatocellular
13
Urinary Bladder Neoplasms
11
Colorectal Neoplasms
11
Small Cell Lung Carcinoma
9
Neoplasms
8
Carcinoma, Transitional Cell
8
Stomach Neoplasms
7
Neoplasm Metastasis
7
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Melanoma
5
Prostatic Neoplasms
4
Glioblastoma
4
Carcinoma, Renal Cell
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Carcinoma, Neuroendocrine
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Turcot syndrome
2
Solid Tumors
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Mesothelioma, Malignant
2
Lymphoma, Follicular
2
Glioma
2
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Anal Cancer Metastatic
×
atezolizumab
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled